Dimopoulos M A, Cabanillas F, Lee J J, Swan F, Fuller L, Allen P K, Hagemeister F B
Department of Hematology, M.D. Anderson Cancer Center, Houston, TX 77030.
J Clin Oncol. 1993 Jun;11(6):1108-11. doi: 10.1200/JCO.1993.11.6.1108.
To evaluate the role of serum beta 2-microglobulin (beta 2M) in the prognosis of patients with Hodgkin's disease.
One hundred sixty previously untreated patients with Hodgkin's disease had serum beta 2M levels determined before initiation of treatment. Serum beta 2M was tested for its correlation with known prognostic factors for patients with Hodgkin's disease. These variables, including beta 2M, were correlated with complete remission (CR) rate and time to treatment failure (TTF). Univariate and multivariate analyses were performed.
Serum beta 2M levels greater than 2.5 mg/L were found in 29% of patients. Such elevation was more common in patients with more advanced-stage disease. Elevated serum beta 2M was an independent and powerful factor in the prediction of lower response rate and shorter TTF. Its impact appeared to be more significant in patients with advanced disease.
Serum beta 2M appears to correlate with tumor stage in patients with Hodgkin's disease and elevated serum levels of this polypeptide predict a less favorable prognosis.
评估血清β2-微球蛋白（β2M）在霍奇金病患者预后中的作用。
160例未经治疗的霍奇金病患者在开始治疗前测定血清β2M水平。检测血清β2M与霍奇金病患者已知预后因素的相关性。这些变量，包括β2M，与完全缓解（CR）率和治疗失败时间（TTF）相关。进行单因素和多因素分析。
29%的患者血清β2M水平高于2.5mg/L。这种升高在疾病分期较晚的患者中更为常见。血清β2M升高是预测缓解率较低和TTF较短的一个独立且有力的因素。其影响在晚期疾病患者中似乎更为显著。
血清β2M似乎与霍奇金病患者的肿瘤分期相关，且该多肽血清水平升高预示预后较差。
